Because HDACis are being evaluated in numerous clinical trials in breast and other solid tumor malignancies, we next investigated whether pharmacologic inhibition of HDAC11 would yield similar effects on LN tumor growth and metastasis. This evidence concerns the gene HDAC11 and neoplasm.